qutavina
eurogenerics holdings b.v. - teriparatide - osteoporosis - calcium homeostasis - qutavina is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
livogiva
theramex ireland limited - teriparatide - osteoporosis - calcium homeostasis - livogiva is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
sondelbay
accord healthcare s.l.u. - teriparatide - osteoporosis - calcium homeostasis - sondelbay is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
kauliv
strides pharma (cyprus) limited - teriparatide - osteoporosis; osteoporosis, postmenopausal - calcium homeostasis - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).,
forteo
eli lilly and company (nz) limited - teriparatide 250 µg/ml (rhpth(1-34)); - solution for injection - 250 mcg/ml - active: teriparatide 250 µg/ml (rhpth(1-34)) excipient: glacial acetic acid hydrochloric acid mannitol metacresol sodium acetate sodium hydroxide water for injection - forteo, in combination with calcium and vitamin d, is indicated for the treatment of osteoporosis in postmenopausal women and in men at high risk of fracture.
forsteo
eli lilly nederland b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - calcium homeostasis - treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and nonvertebral fractures but not hip fractures has been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
megapth-g teriparatide 20 micrograms 80 microliters solution for injection
mega lifesciences sdn. bhd. - teriparatide -
osnuvo solution
avir pharma inc. - teriparatide - solution - 250mcg - teriparatide 250mcg - parathyroid agents
forteo solution
eli lilly canada inc - teriparatide - solution - 250mcg - teriparatide 250mcg - parathyroid agents
terrosa teriparatide (rbe) 250 microgram/ml solution for injection cartridge in a pre-filled pen
gedeon richter australia pty ltd - teriparatide, quantity: 250 microgram/ml - injection, solution - excipient ingredients: metacresol; water for injections; sodium hydroxide; hydrochloric acid; glacial acetic acid; mannitol; sodium acetate trihydrate - terrosa is indicated for the treatment of osteoporosis in postmenopausal women and the treatment of primary osteoporosis in men when other agents are considered unsuitable and when there is a high risk of fractures.,terrosa is indicated for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at high risk for fracture.